Trial · NCT06968559
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major complications | 28 days | It's a hierarchic procedure. Major complications defined as moderate to severe ARDS (using Berlin definition criteria) or AKI KDIGO 2 to 3 within 28 days |
| Primary | All-cause mortality at day 90 | 90 days | |
| Secondary | Hospital-acquired infections | 28 days | Hospital-acquired pneumonia (using the joint definition from the Infectious Diseases Society of America and American Thoracic Society) within 28 days |
| Secondary | Hospital-acquired infections | 28 days | Catheter-related bloodstream infections within 28 daysDiseases Society of America and American Thoracic Society) within 28 days |
| Secondary | Hospital-acquired infections | 28 days | other infections, including skin infections (diagnosis confirmed by an independent adjudication committee) with or without bacteraemia within 28 days |
| Secondary | Hospital-acquired infections | 28 days | Antibiotic-free days on day 28 |
| Secondary | Respiratory complications | 28 days | ARDS (using Berlin Criteria definition) on day 28 |
| Secondary | Respiratory complications | 28 days | Invasive ventilator-free days on day 28 |
| Secondary | ICU Length-of-Stay | 28 days | ICU Length-of-Stay |
| Secondary | Hospital Length-of-Stay | 28 days | Hospital Length-of-Stay |
| Secondary | risks of organ dysfunction | 14 days | SOFA scores |
| Secondary | risks of organ dysfunction | 28 days | KDIGO stages 2 and 3 AKI |
| Secondary | General tolerance of the treatment | 28 days | Number of Participants with Hyperglycemia |
| Secondary | specific tolerance of the treatment on skin lesions | 28 days | surgical site infections confirmed by an independent adjudication committee, |
| Secondary | Timing of first surgery | 28 days | Timing of first surgery on the main endpoint |
| Secondary | Impact of treatment on serum CRP Levels | 14 days | Serum CRP levels on day 0, day 1, day 3, day 7 and day 14 |
| Secondary | General tolerance of the treatment | 28 days | Number of Participants with hypernatremia |
| Secondary | General tolerance of the treatment | 28 days | Number of Participants with hypokalaemia |
| Secondary | General tolerance of the treatment | 28 days | Number of Participants with gastrointestinal bleeding |
| Secondary | General tolerance of the treatment | 28 days | Number of Participants with acquired-weakness |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06968559/registered